A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, first in human (FiH), randomized, double-blind, placebo-controlled, single
ascending dose (SAD) and multiple ascending dose (MAD) study to investigate the safety,
tolerability, PK and PD of DD01 administered by subcutaneous (SC) injection in
overweight/obese subjects with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease
(NAFLD).
The study will be conducted in 2 Parts (Part A and B), with up to 4 cohorts included in each
part (Part A; Cohorts A1 to A4 and Part B; Cohorts B1 to B4).